Clinicopathological Significance and Prognosis of Long Noncoding RNA SNHG16 Expression in Human Cancers: a Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Jul 18

PMID 32677912

Citations 4

Authors

Ruonan Jiao

Wei Jiang

Xin Wei

Mengpei Zhang

Si Zhao

Guangming Huang

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have highlighted the important role of long non-coding RNA SNHG16 in various human cancers. Here, we conducted a meta-analysis to investigate the effect of SNHG16 expression on clinicopathological features and prognosis in patients with different kinds of human cancers.

Methods: We performed a systematic search in electronic databases including PubMed, EMBASE, Cochrane Library and Web of Science, to investigate the potential association between SNHG16 expression and prognostic significance and clinical features in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were pooled to estimate the prognosis value of SNHG16 by StataSE 15.0 software.

Results: A total of 16 eligible studies with 1299 patients were enrolled in our meta-analysis. The results revealed that increased expression level of SNHG16 was significantly associated with larger tumor size (OR: 3.357; 95% CI: 2.173-5.185; P < 0.001), advanced TNM stage (OR: 2.930; 95% CI: 1.522-5.640; P = 0.001) and poor histological grade (OR: 3.943; 95% CI: 1.955-7.952; P < 0.001), but not correlated with smoking status (P = 0.489), sex (P = 0.932), distant metastasis (P = 0.052), or lymph node metastasis (P = 0.155). Moreover, the pooled HR showed that elevated expression SNHG16 was associated with a significantly poorer overall survival (OS) (HR = 1.866, 95% CI: 1.571-2.216, P < 0.001). For the set of cancer types, high expression of SNHG16 was significantly associated with shorter OS in patients with cancers of the urinary system (HR: 2.523, 95% CI:1.540-4.133; P <0.001), digestive system (HR: 2.406, 95% CI:1.556-3.721; P <0.001), and other cancers (including glioma and non-small cell lung cancer) (HR: 1.786, 95% CI:1.406-2.267; P <0.001).

Conclusions: LncRNA SNHG16 overexpression might serve as an unfavorable prognostic factor, which provides a basis for medical workers to evaluate the prognosis of patients and to help the decision-making process.

Citing Articles

Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

Jaszek N, Bogdanowicz A, Siwiec J, Starownik R, Kwasniewski W, Mlak R J Clin Med. 2024; 13(23).

PMID: 39685620 PMC: 11642161. DOI: 10.3390/jcm13237159.

Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review).

Zhao L, Kan Y, Wang L, Pan J, Li Y, Zhu H Oncol Rep. 2024; 52(2).

PMID: 38940337 PMC: 11234248. DOI: 10.3892/or.2024.8765.

The crucial roles of long noncoding RNA SNHGs in lung cancer.

Chen F, Zhang F, Leng Y, Shi Y, Zhang J, Liu Y Clin Transl Oncol. 2022; 24(12):2272-2284.

PMID: 36008615 DOI: 10.1007/s12094-022-02909-5.

Construction of a ceRNA network in glioma and analysis of its clinical significance.

Liu G, Li H, Ji W, Gong H, Jiang Y, Ji G BMC Genomics. 2021; 22(1):722.

PMID: 34615480 PMC: 8496082. DOI: 10.1186/s12864-021-08035-w.

References

Moses C, Garcia-Bloj B, Harvey A, Blancafort P . Hallmarks of cancer: The CRISPR generation. Eur J Cancer. 2018; 93:10-18. DOI: 10.1016/j.ejca.2018.01.002. View

Yuan L, Xu Z, Ruan S, Mo S, Qin J, Cheng X . Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020; 19(1):96. PMC: 7251695. DOI: 10.1186/s12943-020-01219-0. View

Lian D, Amin B, Du D, Yan W . Enhanced expression of the long non-coding RNA SNHG16 contributes to gastric cancer progression and metastasis. Cancer Biomark. 2017; 21(1):151-160. DOI: 10.3233/CBM-170462. View

Cao X, Xu J, Yue D . LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther. 2017; 25(1-2):10-17. DOI: 10.1038/s41417-017-0006-x. View

Peng H, Li H . The encouraging role of long noncoding RNA small nuclear RNA host gene 16 in epithelial-mesenchymal transition of bladder cancer via directly acting on miR-17-5p/metalloproteinases 3 axis. Mol Carcinog. 2019; 58(8):1465-1480. DOI: 10.1002/mc.23028. View

Wang X, Hu K, Chao Y, Wang L . LncRNA SNHG16 promotes proliferation, migration and invasion of osteosarcoma cells by targeting miR-1301/BCL9 axis. Biomed Pharmacother. 2019; 114:108798. DOI: 10.1016/j.biopha.2019.108798. View

Yang X, Wang G, Luo L . Long non-coding RNA SNHG16 promotes cell growth and metastasis in ovarian cancer. Eur Rev Med Pharmacol Sci. 2018; 22(3):616-622. DOI: 10.26355/eurrev_201802_14284. View

Lu Y, Cai X, Li Z, Lv J, Xiang Y, Chen J . LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-4518 and Up-Regulating PRMT5 Expression in Glioma. Cell Physiol Biochem. 2018; 45(5):1975-1985. DOI: 10.1159/000487974. View

Wang Y, Sun B, Wen X, Hao D, Du D, He G . The Roles of lncRNA in Cutaneous Squamous Cell Carcinoma. Front Oncol. 2020; 10:158. PMC: 7059100. DOI: 10.3389/fonc.2020.00158. View

10.

Christensen L, True K, Hamilton M, Nielsen M, Damas N, Damgaard C . SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016; 10(8):1266-82. PMC: 5423192. DOI: 10.1016/j.molonc.2016.06.003. View

11.

Zhou Z, Zhu Y, Gao G, Zhang Y . Long noncoding RNA SNHG16 targets miR-146a-5p/CCL5 to regulate LPS-induced WI-38 cell apoptosis and inflammation in acute pneumonia. Life Sci. 2019; 228:189-197. DOI: 10.1016/j.lfs.2019.05.008. View

12.

Sun C, Huang L, Li Z, Leng K, Xu Y, Jiang X . Long non-coding RNA MIAT in development and disease: a new player in an old game. J Biomed Sci. 2018; 25(1):23. PMC: 5851271. DOI: 10.1186/s12929-018-0427-3. View

13.

Liao S, Xing S, Ma Y . LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma. Cancer Chemother Pharmacol. 2019; 83(6):1065-1074. DOI: 10.1007/s00280-019-03822-5. View

14.

Yu W, Wang H, He Q, Xu Y, Wang X . Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol. 2018; 233(9):6518-6523. DOI: 10.1002/jcp.26568. View

15.

Tang Y, He Y, Zhang P, Wang J, Fan C, Yang L . LncRNAs regulate the cytoskeleton and related Rho/ROCK signaling in cancer metastasis. Mol Cancer. 2018; 17(1):77. PMC: 5885413. DOI: 10.1186/s12943-018-0825-x. View

16.

Lee S, Kopp F, Chang T, Sataluri A, Chen B, Sivakumar S . Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins. Cell. 2016; 164(1-2):69-80. PMC: 4715682. DOI: 10.1016/j.cell.2015.12.017. View

17.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

18.

Chen H, Li M, Huang P . LncRNA SNHG16 Promotes Hepatocellular Carcinoma Proliferation, Migration and Invasion by Regulating miR-186 Expression. J Cancer. 2019; 10(15):3571-3581. PMC: 6603422. DOI: 10.7150/jca.28428. View

19.

Wang X, Kan J, Han J, Zhang W, Bai L, Wu H . LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-135a and Promotes JAK2/STAT3 Signal Pathway in Gastric Cancer. J Cancer. 2019; 10(4):1013-1022. PMC: 6400807. DOI: 10.7150/jca.29527. View

20.

Han W, Du X, Liu M, Wang J, Sun L, Li Y . Increased expression of long non-coding RNA SNHG16 correlates with tumor progression and poor prognosis in non-small cell lung cancer. Int J Biol Macromol. 2018; 121:270-278. DOI: 10.1016/j.ijbiomac.2018.10.004. View